Her scientific interests lie mostly in Acquired immunodeficiency syndrome, Cohort study, Internal medicine, Viral load and Immunology. Margaret T May interconnects Prospective cohort study, Interquartile range, Comorbidity and Confidence interval in the investigation of issues within Acquired immunodeficiency syndrome. Her Cohort study study combines topics in areas such as Mortality rate, Demography, Life expectancy, Antiretroviral therapy and Cohort.
Her study in Internal medicine is interdisciplinary in nature, drawing from both Sida and Surgery. The study incorporates disciplines such as Survival analysis and Pediatrics in addition to Viral load. The various areas that Margaret T May examines in her Hazard ratio study include Proportional hazards model and Risk factor.
Margaret T May mostly deals with Internal medicine, Acquired immunodeficiency syndrome, Cohort, Cohort study and Demography. Her Internal medicine research includes themes of Surgery and Immunology. Her Acquired immunodeficiency syndrome research integrates issues from Mortality rate, Pediatrics, Viral load and Disease.
The concepts of her Cohort study are interwoven with issues in Body mass index, Young adult, Regimen, Pharmacotherapy and Physical therapy. Her research investigates the connection with Cohort study and areas like Risk factor which intersect with concerns in Framingham Risk Score. Her Demography study combines topics from a wide range of disciplines, such as Epidemiology, Incidence and Gerontology.
Her primary areas of investigation include Internal medicine, Cohort, Demography, Acquired immunodeficiency syndrome and Incidence. Her Internal medicine research is multidisciplinary, incorporating perspectives in Endocrinology and Oncology. Margaret T May combines subjects such as Parity, Cohort study and Antiretroviral therapy with her study of Cohort.
In her study, Young adult, Hiv infected patients and Pharmacy is inextricably linked to Viral load, which falls within the broad field of Cohort study. Her studies deal with areas such as Odds ratio and Logistic regression as well as Demography. Her Mortality rate research extends to the thematically linked field of Acquired immunodeficiency syndrome.
Margaret T May spends much of her time researching Internal medicine, Risk factor, Hepatitis C virus, Environmental health and Incidence. Her Cohort, Confidence interval, Hazard ratio and Severity of illness study in the realm of Internal medicine interacts with subjects such as Placebo. Her Hazard ratio research includes elements of Cohort study, Acquired immunodeficiency syndrome, Viral load and Comorbidity.
The Cohort study study combines topics in areas such as Levodopa, Prospective cohort study and Disease. Her work in Viral load addresses issues such as Proportional hazards model, which are connected to fields such as Young adult. Her research integrates issues of Odds ratio, Attributable risk and Hepatitis C in her study of Risk factor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Matthias Egger;Margaret May;Geneviève Chene;Andrew N. Phillips.
The Lancet (2002)
Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects
Yoav Ben-Shlomo;Melissa Spears;Chris Boustred;Margaret May.
Journal of the American College of Cardiology (2014)
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
R Hogg;V Lima;J Sterne;S Grabar.
The Lancet (2008)
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
P Braitstein;Mwg Brinkhof;F Dabis;M Schechter.
The Lancet (2006)
Relation of Particle Dimension to Carcinogenicity in Amphibole Asbestoses and Other Fibrous Minerals
Mearl F. Stanton;Maxwell Layard;Andrew Tegeris;Eliza Miller.
Journal of the National Cancer Institute (1981)
Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study
Julia Hippisley-Cox;Carol Coupland;Yana Vinogradova;John Robson.
BMJ (2007)
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
Jonathan A C Sterne;Margaret May;Dominique Costagliola;Frank de Wolf.
The Lancet (2009)
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Adam Trickey;Margaret T May;Jorg-Janne Vehreschild;Niels Obel.
The Lancet HIV (2017)
Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohort studies
J Gill;Margaret T May;C Lewden;M Saag.
Clinical Infectious Diseases (2010)
Carcinogenicity of Fibrous Glass: Pleural Response in the Rat in Relation to Fiber Dimension
M F Stanton;M Laynard;A Tegeris;E Miller.
Journal of the National Cancer Institute (1977)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Bristol
University of Bern
Yale University
University of Alabama at Birmingham
Sorbonne University
University of Milan
Simon Fraser University
University of Bordeaux
University of Cologne
Vanderbilt University Medical Center
Pennsylvania State University
International Monetary Fund
University of Bath
Ford Motor Company (United States)
University of Granada
Sungkyunkwan University
Mayo Clinic
University of California, Berkeley
Necker-Enfants Malades Hospital
Memorial Sloan Kettering Cancer Center
Cochrane
National University of Singapore
University of Barcelona
University of Padua
New York University
University College London